Astrazeneca

Astrazeneca Company Financial Information

Astrazeneca share price | Astrazeneca company information | Astrazeneca Share Charts | Astrazeneca Share News

Company name:	Astrazeneca
Company Description:	A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
EPIC:	AZN	Trading Currency:	GBX
Market Sector:	FE00	ISIN:	GB0009895292
Market Segment:	SET0	Share Type:	DE
WWW Address:	http://www.astrazeneca.com/	Description:	ORD SHS $0.25
Industry Sector:	PHARMACEUTICALS & BIOTECHNOLOGY

Price	Price Change [%]	Bid	Ask	Open	High	Low	Volume
3,417.50	-9.0 [-0.26]	3,417.00	3,418.00	3,436.50	3,444.50	3,409.50	438,800
Market Cap. [m]	Shares In Issue [m]	Beta	EPS	DPS	PE Ratio	Yield	52-Wks-Range
42,766.20	1,251.39	0.25	330.31	172.30	10.35	5.04	3,487.50 - 2,578.50

Astrazeneca Key Figures

(at previous day's close)
Market Cap.	42,766.20	m
Shares In Issue	1,251.39	m
Prev. Close	3,426.50
PE Ratio	10.35
Dividend Yield	5.04	%
EPS - basic	330.31	p
Dividend PS	172.30	p
Dividend Cover	-
Cash Flow PS	341.65	p
Return On Equity (ROE)	26.53	%
Operating Margin	27.59	%
PEG Factor	-0.32
EPS Growth Rate	-31.92	%
Dividends PS Growth Rate	-	%
Net Debt	13,464.40	m
Gross Gearing	55.26	%
Quick Assets	10,827.64	m
Net Working Capital	3,540.71	m
Intangibles / Fixed Assets	77.77	%
Turnover PS	1,375.52	p
Pre-Tax Profit PS	379.52	p
Retained Profit PS	129.42	p
Cash PS	378.68	p
Net Cash PS	-304.97	p
Net Tangible Asset Value PS *	-128.29	p
Net Asset Value PS	1,177.79	p
Spread	1.00 (0.03%)
* Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies.

Astrazeneca Balance Sheet

Astrazeneca Share Price

Sample Period ^†	High	Low
1 week	3,487.50	3,346.50
4 weeks	3,487.50	3,293.00
12 weeks	3,487.50	2,985.50
1 year	3,487.50	2,578.50

Astrazeneca Share Price (5 years)

Astrazeneca Historic Returns

Giorni da oggi ^†	Open	Change	%	Open Avg.	Avg. Daily Vol [m]	Total Vol [m]	VWAP
1 week	3,389.00	28.50	0.84	3,416.00	2.42		3,428.35
4 weeks	3,304.50	113.00	3.42	3,360.16	2.21		3,367.21
12 weeks	2,992.50	425.00	14.20	3,259.54	2.44		3,258.07
26 weeks	2,875.50	542.00	18.85	3,116.91	2.38		3,120.21
1 year	2,625.00	792.50	30.19	3,000.75	2.41		3,000.22
3 years	2,866.00	551.50	19.24	3,001.81	2.80		2,991.90
5 years	2,218.00	1,199.50	54.08	2,857.66	3.73		2,774.65
† periods calculated are whole weeks rather than calendar months

Astrazeneca Key Management Ratios

Astrazeneca Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio	23.69
PE Ratio	10.35
Tobin's Q Ratio	0.80
Tobin's Q Ratio (excl. intangibles)	1.45
Dividend Yield	5.04	%
Market-to-Book Ratio	2.93
Price-to-Pre-Tax Profit PS	9.00
Price-to-Retained Profit PS	26.41
Price-to-Cash Flow PS	10.00
Price-to-Sales PS	2.48
Price-to-Net Tangible Asset Value PS	-29.03
Price-to-Cash PS	9.02
Net Working Capital PS	282.94
Price Pct to Working Capital PS	12.08	%
Earnings Yield	9.67	%
Average PE	5.47
Years in average	5
PE to PE average	189.23	%

Astrazeneca Financial Ratios

(Leverage Ratios)
Debt Ratio	39.56	%
Debt-to-Equity Ratio	0.65
Debt-to-Equity Ratio (excl. Intgbl)	-6.55
Debt-to-Equity Market Value	0.23
Net Gearing	40.87	%
Net Gearing (excl. Intangibles)	80.48	%
Gross Gearing	55.26	%
Gross Gearing (excl. Intangibles)	108.81	%
Gearing Under 1 Year	25.97	%
Gearing Under 1 Year (excl. Intgbl)	51.14	%
Assets/Equity	2.24
Cash/Equity	32.15
(Liquidity Ratios)
Net Working Capital to Total Assets	10.75	%
Current Ratio	1.41
Quick Ratio (Acid Test)	1.27
Liquidity Ratio	0.55
Cash & Equiv/Current Assets	39.18	%
(Solvency Ratios)
Enterprise Value	47,807.73	m
CFO/Sales	0.25
CFO/Attributable Profit	1.10
CFO/Assets	0.13
CFO/Debt	0.23
Total Debt/Equity Market Value	0.43
Total Debt/Sales	1.06
Total Debt/Pre-Tax Profit	3.83
Total Debt	18,203.19	m
Total Debt/Net Current Assets	5.14	%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth	-	%
5 yr Compound Earnings Growth	3.51	%
10 yr Compound Earnings Growth	10.86	%
Earn drops > 5% in 10yrs	4

Beta (60-Mnth)	Beta (36-Mnth)
0.2485	0.2237

Alpha (60-Mnth)	Alpha (36-Mnth)
0.0079	0.0032

Astrazeneca Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)	19.47	%
Return On Assets (ROA)	7.29	%
Net Profit Margin	22.51	%
Assets Turnover	0.32
Return On Equity (ROE)	26.53	%
Return On Investment (ROI)	10.10	%
Dividend Payout Ratio	56.11	%
Plowback Ratio	43.89	%
Growth from Plowback Ratio	7.24	%
Net Income Of Revenues	9.41	%
(Asset Utilisation Multiples)
Shareholders Equity Turnover	0.73
Fixed Assets Turnover	0.52
Current Assets Turnover	0.85
Net Working Capital Turnover
Inventory Turnover	8.80
(Other Operating Ratios)
Total Assets-to-Sales	3.09
Debtors-to-Sales	61.64	%
Debt Collection Period	224.97	Days

Astrazeneca Dividends

Announcement Date	Type	Curr.	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
31 Jan 2013	Final	USD	190.00	12/31/2011	12/31/2012	02/13/2013	02/15/2013	03/18/2013	280.00
26 Jul 2012	Interim	USD	90.00	12/31/2011	12/31/2012	08/08/2012	08/10/2012	09/10/2012	-
02 Feb 2012	Final	USD	195.00	12/31/2010	12/31/2011	02/15/2012	02/17/2012	03/19/2012	280.00
28 Jul 2011	Interim	USD	85.00	12/31/2010	12/31/2011	08/03/2011	08/05/2011	09/12/2011	-
27 Jan 2011	Final	USD	185.00	12/31/2009	12/31/2010	02/02/2011	02/04/2011	03/14/2011	255.00
29 Jul 2010	Interim	USD	70.00	12/31/2009	12/31/2010	08/02/2010	08/04/2010	09/13/2010	-
28 Jan 2010	Final	USD	171.00	12/31/2008	12/31/2009	02/03/2010	02/05/2010	03/15/2010	230.00
30 Jul 2009	Interim	USD	59.00	12/30/2008	06/30/2009	08/05/2009	08/07/2009	09/14/2009	-
29 Jan 2009	Final	USD	150.00	12/31/2007	12/31/2008	02/04/2009	02/06/2009	03/16/2009	205.00
31 Jul 2008	Interim	USD	55.00	12/30/2007	06/30/2008	08/08/2008	08/06/2008	09/15/2008	-
31 Jan 2008	Final	USD	135.00	12/31/2006	12/31/2007	02/06/2008	02/08/2008	03/17/2008	187.00
26 Jul 2007	Interim	USD	52.00	06/30/2006	06/30/2007	08/08/2007	08/10/2007	09/17/2007	-
01 Feb 2007	Final	USD	123.00	12/31/2005	12/31/2006	02/07/2007	02/09/2007	03/19/2007	172.00
27 Jul 2006	Interim	USD	49.00	12/30/2005	06/30/2006	08/09/2006	08/11/2006	09/18/2006	-
01 Feb 2006	Final	USD	92.00	12/31/2004	12/31/2005	02/08/2006	02/10/2006	03/20/2006	130.00
29 Jul 2005	Interim	USD	38.00	12/30/2004	06/30/2005	08/10/2005	08/12/2005	09/19/2005	-
27 Jan 2005	Final	USD	64.50	12/31/2003	12/31/2004	02/09/2005	02/11/2005	03/21/2005	94.00
22 Jul 2004	Interim	USD	29.50	12/30/2003	06/30/2004	08/11/2004	08/13/2004	09/20/2004	-
29 Jan 2004	Final	USD	54.00	12/31/2002	12/31/2003	02/18/2004	02/20/2004	04/06/2004	79.50
24 Jul 2003	Interim	USD	25.50	12/30/2002	06/30/2003	08/20/2003	08/22/2003	10/06/2003	-
30 Jan 2003	Final	USD	47.00	12/31/2001	12/31/2002	02/19/2003	02/21/2003	04/07/2003	70.00
25 Jul 2002	Interim	USD	23.00	12/30/2001	06/30/2002	08/21/2002	08/23/2002	10/07/2002	-
31 Jan 2002	Final	USD	47.00	12/31/2000	12/31/2001	02/20/2002	02/22/2002	04/08/2002	70.00
26 Jul 2001	Interim	USD	23.00	12/30/2000	06/30/2001	08/22/2001	08/24/2001	10/05/2001	-
08 Feb 2001	Final	USD	47.00	12/31/1999	12/31/2000	02/21/2001	02/23/2001	04/09/2001	70.00
01 Aug 2000	Interim	USD	23.00	12/30/1999	06/30/2000	09/04/2000	09/08/2000	10/23/2000	-
24 Feb 2000	Final	USD	47.00	12/31/1998	12/31/1999	03/06/2000	03/10/2000	04/17/2000	70.00
03 Aug 1999	Interim	USD	23.00	12/30/1998	06/30/1999	09/06/1999	09/10/1999	10/25/1999	-

Astrazeneca Fundamentals

	31 Dec 2009 (USD)		31 Dec 2010 (USD)		31 Dec 2011 (USD)		31 Dec 2012 (USD)
turnover	32,804.00	100.00%	33,269.00	100.00%	33,591.00	100.00%	27,973.00	100.00%	m
pre tax profit	10,807.00	32.94%	10,977.00	32.99%	12,367.00	36.82%	7,718.00	27.59%	m
attributable profit	7,521.00	22.93%	8,053.00	24.21%	9,983.00	29.72%	6,297.00	22.51%	m
retained profit	4,544.00	13.85%	4,692.00	14.10%	6,219.00	18.51%	2,632.00	9.41%	m
eps - basic	519.00		560.00		733.00		499.00
eps - diluted	519.00		557.00		730.00		498.00
dividends per share	230.00		255.00		280.00		280.00

Astrazeneca Balance Sheet

	31 Dec 2009 (USD)		31 Dec 2010 (USD)		31 Dec 2011 (USD)		31 Dec 2012 (USD)


	31 Dec 2009 (USD)		31 Dec 2010 (USD)		31 Dec 2011 (USD)		31 Dec 2012 (USD)
ASSETS
fixed assets	7,307.00	13.30%	6,957.00	12.40%	6,425.00	12.16%	6,089.00	11.37%	m
intangibles	22,115.00	40.27%	22,029.00	39.25%	20,842.00	39.45%	26,346.00	49.21%	m
fixed investments	1,738.00	3.16%	2,026.00	3.61%	4,816.00	9.12%	1,442.00	2.69%	m
current assets - other	-	-%	-	-%	-	-%	-	-%	m
stocks	1,750.00	3.19%	1,682.00	3.00%	1,852.00	3.51%	2,061.00	3.85%	m
debtors	12,092.00	22.02%	12,365.00	22.03%	11,324.00	21.43%	9,895.00	18.48%	m
cash & securities	9,918.00	18.06%	11,068.00	19.72%	7,571.00	14.33%	7,701.00	14.39%	m

TOTAL	54,920.00	100%	56,127.00	100%	52,830.00	100%	53,534.00	100%	m

LIABILITIES
creditors - short	17,640.00	32.12%	16,787.00	29.91%	15,752.00	29.82%	13,903.00	25.97%	m
creditors - long	16,459.00	29.97%	15,930.00	28.38%	13,606.00	25.75%	15,679.00	29.29%	m
creditors - other	-	-%	-	-%	-	-%	-	-%	m
subordinated loans	-	-%	-	-%	-	-%	-	-%	m
insurance funds	-	-%	-	-%	-	-%	-	-%	m

TOTAL	34,099.00	62.09%	32,717.00	58.29%	29,358.00	55.57%	29,582.00	55.26%	m

EQUITY
ord cap, reserves	20,660.00	37.62%	23,213.00	41.36%	23,246.00	44.00%	23,737.00	44.34%	m
prefs, minorities	161.00	0.29%	197.00	0.35%	226.00	0.43%	215.00	0.40%	m

TOTAL	20,821.00	37.91%	23,410.00	41.71%	23,472.00	44.43%	23,952.00	44.74%	m

OTHER
NAV Basic	-		-		-		-
NAV Diluted	-		-		-		-

Astrazeneca Cash Flow Statement

	31 Dec 2009 (USD)	31 Dec 2010 (USD)	31 Dec 2011 (USD)	31 Dec 2012 (USD)
Operating CF	11,739.00	10,680.00	7,821.00	6,948.00	m
Pre-Financing CF	9,263.00	8,340.00	5,799.00	5,089.00	m
Retained CF	5,634.00	1,120.00	-3,522.00	166.00	m

Astrazeneca Brokers

Name	Activity	Type	Mnemonic	Code
Evolution Securities Limited	Market Maker(MME)	Broker/Dealer	EVO	EVBGGB21MMT
Nyenburgh Holding B.V.	Market Maker(MME)	Broker/Dealer	NYBB	NYENNL2B
Winterflood Securities Ltd	Market Maker(MME)	Broker/Dealer	WINS	WNTSGB2LBIC

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's

1 site:2 us lse azn130524 08:03